Development of nanoparticles for clinical use

Nanomedicine

Volumn 9, Issue 9, 2014, Pages 1295-1299

  Skotland, Tore ^a,b   Iversen, Tore Geir ^a,b   Sandvig, Kirsten ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

drug approval; excretion; metabolism; nanoparticles; risk benefit; toxicity

Indexed keywords

NANOPARTICLE; NEW DRUG; DRUG CARRIER;

DEGRADATION; DRUG INDUSTRY; DRUG MARKETING; DRUG SAFETY; EXCRETION; HUMAN; NONHUMAN; NOTE; PRACTICE GUIDELINE; TOTAL QUALITY MANAGEMENT; ANIMAL; DRUG APPROVAL; DRUG DEVELOPMENT; NANOMEDICINE; RISK ASSESSMENT; SAFETY; TRENDS;

ANIMALS; DRUG APPROVAL; DRUG CARRIERS; DRUG DISCOVERY; HUMANS; NANOMEDICINE; NANOPARTICLES; RISK ASSESSMENT; SAFETY;

EID: 84907022790     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.14.81     Document Type: Note

References (25)

1. Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discov. 9, 615-627 (2010
2. Parveen S, Misra R, Sahoo SK. Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine 8, 147-166 (2012
3. Nichols JW, Bae YH. Odyssey of a cancer nanoparticle: from injection site to site of action. Nano Today 7, 606-618 (2012
4. Gozzard D. When is high-dose intravenous iron repletion needed? Assessing new treatment options. Drug Des. Devel. Ther. 5, 51-60 (2011
5. Corot C, Robert P, Idee JM, Port M. Recent advances in iron oxide nanocrystal technology for medical imaging. Adv. Drug Deliv. Rev. 58, 1471-1504 (2006
6. Duncan R, Gaspar R. Nanomedicine(s) under the Microscope. Mol. Pharm. 8, 2101-2141 (2011
7. Skotland T, Iversen TG, Sandvig K. New metal-based nanoparticles for intravenous use: requirements for clinical success with focus on medical imaging. Nanomedicine 6, 730-737 (2010
8. Chauhan VP, Jain RK. Strategies for advancing cancer nanomedicine. Nat. Mater. 12, 958-962 (2013
9. Li C. A targeted approach to cancer imaging and therapy. Nat. Mater. 13, 110-115 (2014
10. Guidance for Industry. Developing medical imaging drug and biological products: part 1: conducting safety assessments. www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidance/ ucm078930.pdf
11. Lee DE, Koo H, Sun IC, Ryu JH, Kim K, Kwon IC. Multifunctional nanoparticles for multimodal imaging and theragnosis. Chem. Soc. Rev. 41, 2656-2672 (2012
12. Nunn AD. The cost of developing imaging agents for routine clinical use. Invest. Radiol. 41, 206-212 (2006
13. Cheng Z, Al ZA, Hui JZ, Muzykantov VR, Tsourkas A. Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science 338, 903-910 (2012
14. Ye L, Yong KT, Liu L et al. A pilot study in non-human primates shows no adverse response to intravenous injection of quantum dots. Nat. Nanotechnol. 7, 453-458 (2012
15. Rofsky NM, Sherry AD, Lenkinski RE. Nephrogenic systemic fibrosis: a chemical perspective. Radiology 247, 608-612 (2008
16. Goldenberg DM. Advancing role of radiolabeled antibodies in the therapy of cancer. Cancer Immunol. Immunother. 52, 281-296 (2003
17. Fang J, Nakamura H, Maeda H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev. 63, 136-151 (2011
18. Editorial: Join the dialogue. Nat. Nanotechnol. 7, 545-545 (2012
19. Crist RM, Grossman JH, Patri AK et al. Common pitfalls in nanotechnology: lessons learned from NCI's nanotechnology characterization laboratory. Integr. Biol. (Camb.) 5, 66-73 (2013
20. Iversen TG, Skotland T, Sandvig K. Endocytosis and intracellular transport of nanoparticles: present knowledge and need for future studies. Nano Today 6, 176-185 (2011
21. Monopoli MP, Aberg C, Salvati A, Dawson KA. Biomolecular coronas provide the biological identity of nanosized materials. Nat. Nanotechnol. 7, 779-786 (2012
22. Tenzer S, Docter D, Kuharev J et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat. Nanotechnol. 8, 772-781 (2013
23. Schipper ML, Iyer G, Koh AL et al. Particle size, surface coating, and PEGylation influence the biodistribution of quantum dots in living mice. Small 5, 126-134 (2009
24. Fadeel B, Feliu N, Vogt C, Abdelmonem AM, Parak WJ. Bridge over troubled waters: understanding the synthetic and biological identities of engineered nanomaterials. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 5, 111-129 (2013
25. Cho EJ, Holback H, Liu KC, Abouelmagd SA, Park J, Yeo Y. Nanoparticle characterization: state of the art, challenges, and emerging technologies. Mol. Pharm. 10, 2093-2110 (2013